Skip to main content
Christine Coyne, MD, Pediatrics, Basking Ridge, NJ

ChristineAnnCoyneMD

Pediatrics • Basking Ridge, NJ

Physician

Join to view full profile

Dr. Coyne is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Coyne's full profile

Already have an account?

  • Office

    150 N Finley Ave
    Basking Ridge, NJ 07920
    Phone+1 908-766-4660
    Fax+1 908-204-9871

Education & Training

  • Tower Health/St. Christopher's Hospital for Children
    Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 1994 - 1997
  • Baylor College of Medicine
    Baylor College of MedicineClass of 1994

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 1998 - 2025
  • PA State Medical License
    PA State Medical License 1995 - 1998
  • American Board of Pediatrics Pediatrics

Press Mentions

  • SCYNEXIS : Announces U.S. Availability of BREXAFEMME (Ibrexafungerp Tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years
    SCYNEXIS : Announces U.S. Availability of BREXAFEMME (Ibrexafungerp Tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 YearsSeptember 27th, 2021
  • SCYNEXIS Announces U.S. Availability of BREXAFEMME® (Ibrexafungerp Tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years
    SCYNEXIS Announces U.S. Availability of BREXAFEMME® (Ibrexafungerp Tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 YearsSeptember 22nd, 2021
  • Innovation on Hold During the Pandemic? FDA Says No with 29 Approvals in First Half of 2021
    Innovation on Hold During the Pandemic? FDA Says No with 29 Approvals in First Half of 2021July 6th, 2021
  • Join now to see all

Dr. Christine Coyne, Dr. Christine Coyne, MD, Dr. C Coyne, Dr. Christine Ann Coyne